About 150 people rallied Saturday to protest feared federal cuts in Medicaid, Medicare and veterans' programs. They heard St.

Q4 2024 Earnings Call Transcript March 6, 2025 Profound Medical Corp. beats earnings expectations. Reported EPS is $-0.2, ...

Fourth quarter 2024 net loss was approximately $4.9 million, or $0.20 per common share, a 45% improvement compared to approximately $8.9 million, or $0.42 per common share, in the three months ended ...

Bone morphogenetic proteins (BMPs) directly affect the osteogenic differentiation of stem cells and are integral to bone ...

Another type of specialized cells, called osteoblasts, produce a protein-rich compound known as osteoid. This, along with various growth factors, is deposited on the bone. It fills in the gaps ...

At close: 3:42:21 p.m. EDT Loading Chart for PRN.TO ...

palliative pain treatment and osteoid osteoma; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO ®. Often, but not always, forward-looking statements can be ...

This valuable study reports the link between a disruption in testicular mineral (phosphate) homeostasis, FGF23 expression, and Sertoli cell dysfunction. The data supporting the conclusion are solid.

Another type of specialized cells, called osteoblasts, produce a protein-rich compound known as osteoid. This, along with various growth factors, is deposited on the bone. It fills in the gaps with ...

Profound Medical Corp (TICKER: PROF), with a market capitalization of $217 million, reported its earnings for Q4 2024, showcasing a notable improvement in financial performance. The company achieved ...